STUDY OF TAMOXIFEN AND RALOXIFENE (STAR) FOR THE PREVENTION OF BREAST CANCER

他莫昔芬和雷洛昔芬（STAR）预防乳腺癌的研究

• 批准号: 7604953
• 负责人: JOHN HARRIS WARD
• 金额: $ 1.97万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604953
• 关键词: Adverse effects; Breast Cancer Prevention; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; Health protection; Incidence; Institution; Osteoporosis prevention; Postmenopause; Raloxifene; Randomized; Research; Research Personnel; Resources; Risk; Source; Study of Tamoxifen and Raloxifene; Tamoxifen; Thinking; Time; United States Food and Drug Administration; United States National Institutes of Health; Woman; bone; malignant breast neoplasm

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of postmenopausal women at increased risk for breast cancer who are randomized to either Tamoxifen or Raloxifene to determine which is most effective with the least amount of side effects. Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal (women who have stopped menstruating). Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项针对乳腺癌风险增加的绝经后妇女的研究，她们被随机服用他莫昔芬或雷洛昔芬，以确定哪种药物最有效且副作用最少。 一项大型临床试验的证据表明，他莫昔芬有助于降低乳腺癌风险增加的女性的发病率。 美国食品和药物管理局 (FDA) 已批准他莫昔芬用于此类用途。 雷洛昔芬已获得 FDA 和加拿大健康保护部门 (HPB) 的批准，用于预防绝经后（月经停止的女性）骨质疏松症（骨骼变薄）。 研究人员认为雷洛昔芬还可以降低患乳腺癌的风险，并且副作用比他莫昔芬更少。 FDA 和 HPB 认为目前使用雷洛昔芬降低乳腺癌风险尚处于实验阶段。